Kiadis-Kenner schreef op 13 september 2019 09:14:
Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell
transplantation (HSCT) for a malignant disease
Scope: List of Outstanding Issues (LoOIs)
Action: for adoption
List of Outstanding Issues adopted on 14.09.2018, 25.05.2018. List of Questions adopted
on 08.09.2017.
The Rapporteurs presented their assessment of the responses to the second List of
Outstanding Issues. CAT subsequently adopted the third List of Outstanding Issues.
CAT agreed with the proposal to organise an Ad-Hoc Expert Group to provide input to the
CAT . CAT adopted the list of questions to the Ad-hoc expert group. A request for
nomination of experts will be sent to CAT and CHMP.
CAT adopted the review timetable.
Post-meeting note: CHMP proposed amendments to the list of questions to the Ad-hoc
expert group.